Novel computational approaches to polypharmacology as a means to define responses to individual drugs.

Polypharmacology, which focuses on designing therapeutics to target multiple receptors, has emerged as a new paradigm in drug discovery. Polypharmacological effects are an attribute of most, if not all, drug molecules. The efficacy and toxicity of drugs, whether designed as single- or multitarget therapeutics, result from complex interactions between pharmacodynamic, pharmacokinetic, genetic, epigenetic, and environmental factors. Ultimately, to predict a drug response phenotype, it is necessary to understand the change in information flow through cellular networks resulting from dynamic drug-target interactions and the impact that this has on the complete biological system. Although such is a future objective, we review recent progress and challenges in computational techniques that enable the prediction and analysis of in vitro and in vivo drug-response phenotypes.

[1]  Eyke Hüllermeier,et al.  SEGA: Semiglobal Graph Alignment for Structure-Based Protein Comparison , 2011, IEEE/ACM Transactions on Computational Biology and Bioinformatics.

[2]  C. Hirschhäuser,et al.  Paraoxonase-1 is a major determinant of clopidogrel efficacy , 2011, Nature Medicine.

[3]  Lei Xie,et al.  Structure-based systems biology for analyzing off-target binding. , 2011, Current opinion in structural biology.

[4]  Philip E. Bourne,et al.  Drug Discovery Using Chemical Systems Biology: Weak Inhibition of Multiple Kinases May Contribute to the Anti-Cancer Effect of Nelfinavir , 2011, PLoS Comput. Biol..

[5]  John P. Overington,et al.  Probing the links between in vitro potency, ADMET and physicochemical parameters , 2011, Nature Reviews Drug Discovery.

[6]  H Steven Wiley,et al.  Integrating Multiple Types of Data for Signaling Research: Challenges and Opportunities , 2011, Science Signaling.

[7]  Olga G. Troyanskaya,et al.  Accurate Quantification of Functional Analogy among Close Homologs , 2011, PLoS Comput. Biol..

[8]  Wei Liu,et al.  A Mathematical Framework for Protein Structure Comparison , 2011, PLoS Comput. Biol..

[9]  Ferran Sanz,et al.  A Multiscale Simulation System for the Prediction of Drug-Induced Cardiotoxicity , 2011, J. Chem. Inf. Model..

[10]  Jason Weston,et al.  Detecting Remote Evolutionary Relationships among Proteins by Large-Scale Semantic Embedding , 2011, PLoS Comput. Biol..

[11]  J. Skolnick,et al.  Structural space of protein–protein interfaces is degenerate, close to complete, and highly connected , 2010, Proceedings of the National Academy of Sciences.

[12]  Douglas A Lauffenburger,et al.  A mammalian functional-genetic approach to characterizing cancer therapeutics. , 2010, Nature chemical biology.

[13]  Yang Li,et al.  Critical reasoning on causal inference in genome-wide linkage and association studies. , 2010, Trends in genetics : TIG.

[14]  Kevin Y. Yip,et al.  Extensive In Vivo Metabolite-Protein Interactions Revealed by Large-Scale Systematic Analyses , 2010, Cell.

[15]  Philip E. Bourne,et al.  PROMISCUOUS: a database for network-based drug-repositioning , 2010, Nucleic Acids Res..

[16]  Karsten Zengler,et al.  The challenges of integrating multi-omic data sets. , 2010, Nature chemical biology.

[17]  Philip E. Bourne,et al.  The Mycobacterium tuberculosis Drugome and Its Polypharmacological Implications , 2010, PLoS Comput. Biol..

[18]  Tudor I. Oprea,et al.  ChemProt: a disease chemical biology database , 2010, Nucleic Acids Res..

[19]  Dan S. Tawfik Messy biology and the origins of evolutionary innovations. , 2010, Nature chemical biology.

[20]  Jeffrey Skolnick,et al.  iAlign: a method for the structural comparison of protein-protein interfaces , 2010, Bioinform..

[21]  Peer Bork,et al.  Drug-Induced Regulation of Target Expression , 2010, PLoS Comput. Biol..

[22]  Philip E. Bourne,et al.  Drug Off-Target Effects Predicted Using Structural Analysis in the Context of a Metabolic Network Model , 2010, PLoS Comput. Biol..

[23]  A. Armaou,et al.  Development of a stochastic model for the efficacy of NRTIs using known mechanisms of action. , 2010, Journal of theoretical biology.

[24]  R. Tagliaferri,et al.  Discovery of drug mode of action and drug repositioning from transcriptional responses , 2010, Proceedings of the National Academy of Sciences.

[25]  Stéphanie Pérot,et al.  Druggable pockets and binding site centric chemical space: a paradigm shift in drug discovery. , 2010, Drug discovery today.

[26]  Barry Honig,et al.  VASP: A Volumetric Analysis of Surface Properties Yields Insights into Protein-Ligand Binding Specificity , 2010, PLoS Comput. Biol..

[27]  P. Tonge,et al.  Drug-target residence time: critical information for lead optimization. , 2010, Current opinion in chemical biology.

[28]  Andreas Schmid,et al.  Systems biology: Hypothesis-driven omics integration. , 2010, Nature chemical biology.

[29]  W. Hahn,et al.  On or Off Target: Mutations, Models, and Predictions , 2010, Science Translational Medicine.

[30]  Raquel Norel,et al.  Protein interface conservation across structure space , 2010, Proceedings of the National Academy of Sciences.

[31]  Bin Chen,et al.  Chem2Bio2RDF: a semantic framework for linking and data mining chemogenomic and systems chemical biology data , 2010, BMC Bioinformatics.

[32]  Gisbert Schneider,et al.  Virtual screening: an endless staircase? , 2010, Nature Reviews Drug Discovery.

[33]  M. Belvin,et al.  RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth , 2010, Nature.

[34]  Chao Zhang,et al.  RAF inhibitors transactivate RAF dimers and ERK signaling in cells with wild-type BRAF , 2010, Nature.

[35]  K. Chou,et al.  Predicting Drug-Target Interaction Networks Based on Functional Groups and Biological Features , 2010, PloS one.

[36]  Jean-Philippe Vert,et al.  A new protein binding pocket similarity measure based on comparison of clouds of atoms in 3D: application to ligand prediction , 2010, BMC bioinformatics.

[37]  Pedro J Ballester,et al.  Prospective virtual screening with Ultrafast Shape Recognition: the identification of novel inhibitors of arylamine N-acetyltransferases , 2010, Journal of The Royal Society Interface.

[38]  Joel Dudley,et al.  Network-Based Elucidation of Human Disease Similarities Reveals Common Functional Modules Enriched for Pluripotent Drug Targets , 2010, PLoS Comput. Biol..

[39]  K. Shokat,et al.  Targeting the cancer kinome through polypharmacology , 2010, Nature Reviews Cancer.

[40]  J. Fletcher,et al.  ABC transporters in cancer: more than just drug efflux pumps , 2010, Nature Reviews Cancer.

[41]  Valerie A. Braz,et al.  Efavirenz binding to HIV-1 reverse transcriptase monomers and dimers. , 2010, Biochemistry.

[42]  Jie Wu,et al.  BSSF: a fingerprint based ultrafast binding site similarity search and function analysis server , 2010, BMC Bioinformatics.

[43]  J. Reis-Filho,et al.  Kinase-Dead BRAF and Oncogenic RAS Cooperate to Drive Tumor Progression through CRAF , 2010, Cell.

[44]  Owen J. Sansom,et al.  Genetic Dissection of Differential Signaling Threshold Requirements for the Wnt/β-Catenin Pathway In Vivo , 2010, PLoS genetics.

[45]  J. C. Pastor-Pareja,et al.  Interaction between RasV12 and scribble clones induces tumour growth and invasion , 2009, Nature.

[46]  James E Ferrell,et al.  Signaling motifs and Weber's law. , 2009, Molecular cell.

[47]  M. Cyert,et al.  Cracking the Phosphatase Code: Docking Interactions Determine Substrate Specificity , 2009, Science Signaling.

[48]  Damian Szklarczyk,et al.  STITCH 2: an interaction network database for small molecules and proteins , 2009, Nucleic Acids Res..

[49]  A. Fliri,et al.  Drug effects viewed from a signal transduction network perspective. , 2009, Journal of medicinal chemistry.

[50]  Aleksandar Poleksic,et al.  Algorithms for optimal protein structure alignment , 2009, Bioinform..

[51]  Ruili Huang,et al.  Comprehensive Characterization of Cytochrome P450 Isozyme Selectivity across Chemical Libraries , 2009, Nature Biotechnology.

[52]  Dana Pe'er,et al.  Harnessing gene expression to identify the genetic basis of drug resistance , 2009, Molecular systems biology.

[53]  Michael J. Keiser,et al.  Predicting new molecular targets for known drugs , 2009, Nature.

[54]  J. Mestres,et al.  Conciliating binding efficiency and polypharmacology. , 2009, Trends in pharmacological sciences.

[55]  Bin Chen,et al.  PubChem as a Source of Polypharmacology , 2009, J. Chem. Inf. Model..

[56]  Najeeb M. Halabi,et al.  Protein Sectors: Evolutionary Units of Three-Dimensional Structure , 2009, Cell.

[57]  Michael Nilges,et al.  Shelling the Voronoi interface of protein–protein complexes reveals patterns of residue conservation, dynamics, and composition , 2009, Proteins.

[58]  Guanghui Hu,et al.  Human Disease-Drug Network Based on Genomic Expression Profiles , 2009, PloS one.

[59]  Daniel E. Newburger,et al.  Diversity and Complexity in DNA Recognition by Transcription Factors , 2009, Science.

[60]  Yanli Wang,et al.  PubChem: a public information system for analyzing bioactivities of small molecules , 2009, Nucleic Acids Res..

[61]  Hiroki Kobayashi,et al.  Integrating Statistical Predictions and Experimental Verifications for Enhancing Protein-Chemical Interaction Predictions in Virtual Screening , 2009, PLoS Comput. Biol..

[62]  Eric K. Neumann,et al.  Inferring novel disease indications for known drugs by semantically linking drug action and disease mechanism relationships , 2009, BMC Bioinformatics.

[63]  Philip E. Bourne,et al.  Drug Discovery Using Chemical Systems Biology: Identification of the Protein-Ligand Binding Network To Explain the Side Effects of CETP Inhibitors , 2009, PLoS Comput. Biol..

[64]  J. Ferrell,et al.  Tuning the Activation Threshold of a Kinase Network by Nested Feedback Loops , 2009, Science.

[65]  P. Sorger,et al.  Non-genetic origins of cell-to-cell variability in TRAIL-induced apoptosis , 2009, Nature.

[66]  Eugenio Uriarte,et al.  Alignment-free prediction of a drug-target complex network based on parameters of drug connectivity and protein sequence of receptors. , 2009, Molecular pharmaceutics.

[67]  Paul W Finn,et al.  Ultrafast shape recognition: evaluating a new ligand-based virtual screening technology. , 2009, Journal of molecular graphics & modelling.

[68]  P. Tonge,et al.  Slow-onset inhibition of the FabI enoyl reductase from francisella tularensis: residence time and in vivo activity. , 2009, ACS chemical biology.

[69]  Lei Wu,et al.  The anti-cancer drug lenalidomide inhibits angiogenesis and metastasis via multiple inhibitory effects on endothelial cell function in normoxic and hypoxic conditions. , 2009, Microvascular research.

[70]  R. Altman,et al.  Estimation of the warfarin dose with clinical and pharmacogenetic data. , 2009, The New England journal of medicine.

[71]  R. Fässler,et al.  Genetic and cell biological analysis of integrin outside-in signaling. , 2009, Genes & development.

[72]  Diego di Bernardo,et al.  Identifying Network of Drug Mode of Action by Gene Expression Profiling , 2009, J. Comput. Biol..

[73]  Angelo D. Favia,et al.  Protein promiscuity and its implications for biotechnology , 2009, Nature Biotechnology.

[74]  Xiaohua Ma,et al.  Mechanisms of drug combinations: interaction and network perspectives , 2009, Nature Reviews Drug Discovery.

[75]  A. Hopkins Network pharmacology: the next paradigm in drug discovery. , 2008, Nature chemical biology.

[76]  K. Shokat,et al.  Targeted polypharmacology: Discovery of dual inhibitors of tyrosine and phosphoinositide kinases , 2008, Nature chemical biology.

[77]  G. Parmigiani,et al.  Core Signaling Pathways in Human Pancreatic Cancers Revealed by Global Genomic Analyses , 2008, Science.

[78]  D. Busam,et al.  An Integrated Genomic Analysis of Human Glioblastoma Multiforme , 2008, Science.

[79]  R. Solé,et al.  Data completeness—the Achilles heel of drug-target networks , 2008, Nature Biotechnology.

[80]  Didier Rognan,et al.  How to Measure the Similarity Between Protein Ligand-Binding Sites? , 2008 .

[81]  P. Bork,et al.  Drug Target Identification Using Side-Effect Similarity , 2008, Science.

[82]  Yoshihiro Yamanishi,et al.  Prediction of drug–target interaction networks from the integration of chemical and genomic spaces , 2008, ISMB.

[83]  A. Singleton,et al.  Rare Structural Variants Disrupt Multiple Genes in Neurodevelopmental Pathways in Schizophrenia , 2008, Science.

[84]  Emma Griffiths,et al.  Rifamycin antibiotic resistance by ADP-ribosylation: Structure and diversity of Arr , 2008, Proceedings of the National Academy of Sciences.

[85]  Jacob D. Feala,et al.  Search Algorithms as a Framework for the Optimization of Drug Combinations , 2008, PLoS Comput. Biol..

[86]  E. Segal,et al.  Predicting expression patterns from regulatory sequence in Drosophila segmentation , 2008, Nature.

[87]  David S. Wishart,et al.  DrugBank: a knowledgebase for drugs, drug actions and drug targets , 2007, Nucleic Acids Res..

[88]  Robert B. Russell,et al.  SuperTarget and Matador: resources for exploring drug-target relationships , 2007, Nucleic Acids Res..

[89]  A. Barabasi,et al.  Drug—target network , 2007, Nature Biotechnology.

[90]  R. Lange,et al.  The targets of currently used antibacterial agents: lessons for drug discovery. , 2007, Current pharmaceutical design.

[91]  P. Clemons,et al.  Chemogenomic data analysis: prediction of small-molecule targets and the advent of biological fingerprint. , 2007, Combinatorial chemistry & high throughput screening.

[92]  Liang Shen,et al.  Distribution patterns of small-molecule ligands in the protein universe and implications for origin of life and drug discovery , 2007, Genome Biology.

[93]  István A. Kovács,et al.  How to design multi-target drugs , 2007, Expert opinion on drug discovery.

[94]  David J. Mooney,et al.  Microenvironmental regulation of biomacromolecular therapies , 2007, Nature Reviews Drug Discovery.

[95]  Ronald Koschny,et al.  The promise of TRAIL—potential and risks of a novel anticancer therapy , 2007, Journal of Molecular Medicine.

[96]  H. Kitano A robustness-based approach to systems-oriented drug design , 2007, Nature Reviews Drug Discovery.

[97]  Richard Morphy,et al.  Fragments, network biology and designing multiple ligands. , 2007, Drug discovery today.

[98]  Michael J. Keiser,et al.  Relating protein pharmacology by ligand chemistry , 2007, Nature Biotechnology.

[99]  Xin Wen,et al.  BindingDB: a web-accessible database of experimentally determined protein–ligand binding affinities , 2006, Nucleic Acids Res..

[100]  Bruce N. Ames,et al.  Low micronutrient intake may accelerate the degenerative diseases of aging through allocation of scarce micronutrients by triage , 2006, Proceedings of the National Academy of Sciences.

[101]  Philip E. Bourne,et al.  Modern proteomes contain putative imprints of ancient shifts in trace metal geochemistry , 2006, Proceedings of the National Academy of Sciences.

[102]  Marc S. Cortese,et al.  Rational drug design via intrinsically disordered protein. , 2006, Trends in biotechnology.

[103]  T. Golub,et al.  Gene expression-based chemical genomics identifies rapamycin as a modulator of MCL1 and glucocorticoid resistance. , 2006, Cancer cell.

[104]  Paul A Clemons,et al.  The Connectivity Map: Using Gene-Expression Signatures to Connect Small Molecules, Genes, and Disease , 2006, Science.

[105]  R. Weinshilboum,et al.  Pharmacogenetics and pharmacogenomics: development, science, and translation. , 2006, Annual review of genomics and human genetics.

[106]  R. Copeland,et al.  Drug–target residence time and its implications for lead optimization , 2006, Nature Reviews Drug Discovery.

[107]  L. Piddock Multidrug-resistance efflux pumps ? not just for resistance , 2006, Nature Reviews Microbiology.

[108]  J C Reed,et al.  Comparison of chemical inhibitors of antiapoptotic Bcl-2-family proteins , 2006, Cell Death and Differentiation.

[109]  Amos Tanay,et al.  Extensive low-affinity transcriptional interactions in the yeast genome. , 2006, Genome research.

[110]  G. V. Paolini,et al.  Global mapping of pharmacological space , 2006, Nature Biotechnology.

[111]  Meir Glick,et al.  Prediction of Biological Targets for Compounds Using Multiple-Category Bayesian Models Trained on Chemogenomics Databases , 2006, J. Chem. Inf. Model..

[112]  B. Palsson,et al.  The model organism as a system: integrating 'omics' data sets , 2006, Nature Reviews Molecular Cell Biology.

[113]  John P. Overington,et al.  Can we rationally design promiscuous drugs? , 2006, Current opinion in structural biology.

[114]  P. Ridker,et al.  Anti-Inflammatory Effects of Statins: Clinical Evidence and Basic Mechanisms , 2005, Nature Reviews Drug Discovery.

[115]  Joseph Loscalzo,et al.  Cyclooxygenase inhibition and cardiovascular risk. , 2005, Circulation.

[116]  T. Klabunde,et al.  GPCR Antitarget Modeling: Pharmacophore Models for Biogenic Amine Binding GPCRs to Avoid GPCR‐Mediated Side Effects , 2005, Chembiochem : a European journal of chemical biology.

[117]  J. A. Grant,et al.  A shape-based 3-D scaffold hopping method and its application to a bacterial protein-protein interaction. , 2005, Journal of medicinal chemistry.

[118]  J. Jenkins,et al.  A 3D similarity method for scaffold hopping from known drugs or natural ligands to new chemotypes. , 2004, Journal of medicinal chemistry.

[119]  S. Pongor,et al.  Multiple weak hits confuse complex systems: a transcriptional regulatory network as an example. , 2004, Physical review. E, Statistical, nonlinear, and soft matter physics.

[120]  M. Congreve,et al.  Fragment-based lead discovery , 2004, Nature Reviews Drug Discovery.

[121]  P. Csermely Strong links are important, but weak links stabilize them. , 2004, Trends in biochemical sciences.

[122]  S. Lipton Turning down, but not off , 2004, Nature.

[123]  J. Whisstock,et al.  Prediction of protein function from protein sequence and structure , 2003, Quarterly Reviews of Biophysics.

[124]  Tony Pawson,et al.  Multisite phosphorylation of a CDK inhibitor sets a threshold for the onset of DNA replication , 2001, Nature.

[125]  F. Cohen,et al.  Co-evolution of proteins with their interaction partners. , 2000, Journal of molecular biology.

[126]  Ajay N. Jain Morphological similarity: A 3D molecular similarity method correlated with protein-ligand recognition , 2000, J. Comput. Aided Mol. Des..

[127]  Yvonne C. Martin,et al.  Use of Structure-Activity Data To Compare Structure-Based Clustering Methods and Descriptors for Use in Compound Selection , 1996, J. Chem. Inf. Comput. Sci..

[128]  K. Lewis,et al.  Multidrug resistance pumps in bacteria: variations on a theme. , 1994, Trends in biochemical sciences.

[129]  Qing Yan Membrane transporters and drug development: relevance to pharmacogenomics, nutrigenomics, epigenetics, and systems biology. , 2010, Methods in molecular biology.

[130]  P Schneider,et al.  Self-organizing maps in drug discovery: compound library design, scaffold-hopping, repurposing. , 2009, Current medicinal chemistry.

[131]  D. Kell,et al.  'Metabolite-likeness' as a criterion in the design and selection of pharmaceutical drug libraries. , 2009, Drug discovery today.

[132]  Alexandre Varnek,et al.  Chemoinformatics approaches to virtual screening , 2008 .

[133]  John A. Tallarico,et al.  Integrating high-content screening and ligand-target prediction to identify mechanism of action. , 2008, Nature chemical biology.

[134]  Justin Lamb,et al.  The Connectivity Map: a new tool for biomedical research , 2007, Nature Reviews Cancer.

[135]  K. Yoshikawa,et al.  Weak interaction induces an ON/OFF switch, whereas strong interaction causes gradual change: folding transition of a long duplex DNA chain by poly-L-lysine. , 2007, Biomacromolecules.

[136]  Martin Serrano,et al.  Nucleic Acids Research Advance Access published October 18, 2007 ChemBank: a small-molecule screening and , 2007 .

[137]  Jerry J Buccafusco,et al.  Multi-functional drugs for various CNS targets in the treatment of neurodegenerative disorders. , 2005, Trends in pharmacological sciences.

[138]  X. Chen,et al.  TTD: Therapeutic Target Database , 2002, Nucleic Acids Res..

[139]  Joshua M. Stuart,et al.  Integrating genotype and phenotype information: an overview of the PharmGKB project , 2001, The Pharmacogenomics Journal.

[140]  Osman F. Güner,et al.  Pharmacophore perception, development, and use in drug design , 2000 .